efavirenz - Profile

What are the generic drug sources for efavirenz and what is the scope of patent protection?

Efavirenz is the generic ingredient in nine branded drugs marketed by Aurobindo Pharma, Bristol Myers Squibb, Aurobindo Pharma Ltd, Cipla, Hetero Labs Ltd Iii, Macleods Pharms Ltd, Mylan, Pharmobedient, Strides Pharma, Gilead Sciences, Hetero Labs Ltd V, Laurus, Teva Pharms Usa, Chartwell Rx, and Mylan Labs Ltd, and is included in twenty-six NDAs. There are three patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

There are eighteen tentative approvals for this compound.

Summary for efavirenz

US Patents:	3
Tradenames:	9
Applicants:	15
NDAs:	26
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for efavirenz

Generic filers with tentative approvals for EFAVIRENZ

Applicant	Application No.	Strength	Dosage Form
		200MG	TABLET; ORAL
		100MG	TABLET; ORAL
		50MG	TABLET; ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Paragraph IV (Patent) Challenges for EFAVIRENZ

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
SUSTIVA	Capsules	efavirenz	50 mg, 100 mg and 200 mg	020972	1	2016-11-03
SUSTIVA	Tablets	efavirenz	600 mg	021360	1	2009-04-09

US Patents and Regulatory Information for efavirenz

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Aurobindo Pharma	EFAVIRENZ	efavirenz	CAPSULE;ORAL	078064-001	Dec 15, 2017		RX	No	No
Aurobindo Pharma	EFAVIRENZ	efavirenz	CAPSULE;ORAL	078064-002	Dec 15, 2017		RX	No	No
Aurobindo Pharma	EFAVIRENZ	efavirenz	CAPSULE;ORAL	078064-003	Dec 15, 2017		RX	No	Yes
Bristol Myers Squibb	SUSTIVA	efavirenz	CAPSULE;ORAL	020972-001	Sep 17, 1998		DISCN	Yes	No
Bristol Myers Squibb	SUSTIVA	efavirenz	CAPSULE;ORAL	020972-002	Sep 17, 1998		DISCN	Yes	No
Bristol Myers Squibb	SUSTIVA	efavirenz	CAPSULE;ORAL	020972-003	Sep 17, 1998		DISCN	Yes	No

Expired US Patents for efavirenz

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bristol Myers Squibb	SUSTIVA	efavirenz	CAPSULE;ORAL	020972-002	Sep 17, 1998	5,519,021*PED
Bristol Myers Squibb	SUSTIVA	efavirenz	TABLET;ORAL	021360-001	Feb 1, 2002	5,663,169*PED
Bristol Myers Squibb	SUSTIVA	efavirenz	TABLET;ORAL	021360-002	Feb 1, 2002	5,519,021*PED
Bristol Myers Squibb	SUSTIVA	efavirenz	CAPSULE;ORAL	020972-001	Sep 17, 1998	5,519,021*PED
Bristol Myers Squibb	SUSTIVA	efavirenz	CAPSULE;ORAL	020972-003	Sep 17, 1998	6,639,071*PED
Bristol Myers Squibb	SUSTIVA	efavirenz	CAPSULE;ORAL	020972-003	Sep 17, 1998	6,555,133*PED

EU/EMA Drug Approvals for efavirenz

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Teva B.V.	Efavirenz Teva	efavirenz	EMEA/H/C/002352Efavirenz is indicated in antiviral combination treatment of human-immunodeficiency-virus-1 (HIV-1)-infected adults, adolescents and children 3 years of age and older.Efavirenz has not been adequately studied in patients with advanced HIV disease, namely in patients with CD4 counts < 50 cells/mm3, or after failure of protease inhibitor (PI)-containing regimens. Although cross-resistance of efavirenz with protease inhibitors (PIs) has not been documented, there are at present insufficient data on the efficacy of subsequent use of PI-based combination therapy after failure of regimens containing efavirenz.	Authorised	yes	no	no	2012-01-09
Merck Sharp & Dohme B.V.	Stocrin	efavirenz	EMEA/H/C/000250Stocrin is indicated in antiviral combination treatment of human-immunodeficiency-virus-1 (HIV-1)-infected adults, adolescents and children three years of age and older.Stocrin has not been adequately studied in patients with advanced HIV disease, namely in patients with CD4 counts < 50 cells/mm3, or after failure of protease-inhibitor (PI)-containing regimens. Although cross-resistance of efavirenz with PIs has not been documented, there are at present insufficient data on the efficacy of subsequent use of PI-based combination therapy after failure of regimens containing Stocrin.	Authorised	no	no	no	1999-05-28
Bristol-Myers Squibb Pharma EEIG	Sustiva	efavirenz	EMEA/H/C/000249Sustiva is indicated in antiviral combination treatment of human-immunodeficiency-virus-1 (HIV-1)-infected adults, adolescents and children three years of age and older.Sustiva has not been adequately studied in patients with advanced HIV disease, namely in patients with CD4 counts < 50 cells/mm3, or after failure of protease-inhibitor (PI)-containing regimens. Although cross-resistance of efavirenz with PIs has not been documented, there are at present insufficient data on the efficacy of subsequent use of PI-based combination therapy after failure of regimens containing Sustiva.	Authorised	no	no	no	1999-05-28

EFAVIRENZ: Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

---

Executive Summary

Efavirenz, marketed under the brand name Sustiva among others, is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used primarily in HIV-1 treatment. While generic formulations have significantly impacted its market, efavirenz remains a critical component within antiretroviral therapy (ART). This analysis assesses efavirenz's current investment landscape, market dynamics, and financial trajectory, considering factors like patent status, market penetration, competition, regulatory policies, and emerging trends in HIV treatment.

---

1. Product Overview and Pharmacological Profile

Feature	Details
Drug Class	NNRTI (Non-Nucleoside Reverse Transcriptase Inhibitor)
Generic Status	Widely genericized since patent expiration (2018) in many markets
Approved Uses	HIV-1 infection in combination therapies
Formulations	Oral tablets, dispersible tablets (format variations)
Marketed By	Multiple pharmaceutical companies globally

Key Points:

• Efavirenz remains a frontline component for HIV therapy particularly in low- and middle-income countries due to its efficacy and affordability.
• The pharmacokinetic profile facilitates once-daily dosing, enhancing patient adherence.

---

2. Investment Scenario

Market Segmentation

Segment	Market Share (%)	Key Players	Market Size (USD)	Growth Outlook
Emerging Markets	60-70%	Multiple generics	$1.2 billion (2022)	CAGR 4-6% (2023-2030)
Developed Markets	30-40%	Initial patent holder (Bristol-Myers Squibb, etc.)	$800 million (2022)	Declining due to generics

Revenue Drivers

• Generic Penetration: Dominant in Africa, India, Southeast Asia.
• Pricing Trends: Significant decline (~80%) post-patent expiry; generics pricing compels margin compression.
• Distribution Channels: Government procurement programs, NGOs, private sectors.
• Patent Litigations and Disputes: Minimal post-2018, with a focus on quality assurance.

Key Political and Economic Factors

• Pricing Policies: Funding constraints in LMICs influence procurement.
• Regulatory Environment: WHO prequalification (2003), essential medicines listing (WHO, 2005) foster broad access.
• International Aid and Policies: PEPFAR, Global Fund stable demand sources.

---

3. Market Dynamics

Competitive Landscape

Entity	Market Strategy	Strengths	Weaknesses
Generics Suppliers	Price competition	Cost advantage, broad access	Quality perceptions, patent challenges in some regions
Innovative Formulations	Extended-release, fixed-dose combinations	Potential for enhanced adherence	Higher development costs, limited immediate revenue
New HIV Therapies	Integrase inhibitors, long-acting injectables	Superior safety profiles	Expensive, limited access in LMICs

Key Market Factors

• Patent Expirations: Facilitated generics’ entry, severely impacting innovator margins.
• Regulatory Approvals: Sufficient for wide approval due to established safety profile.
• Healthcare Policies: Shift toward integrase inhibitors in high-income countries; efavirenz maintained by cost considerations in LMICs.
• Emerging Resistance: Reports of NNRTI resistance influence prescribing patterns.

---

4. Financial Trajectory and Forecasting

Historical Revenue Trends

Year	Estimated Revenue (USD)	Notes
2015	$1.0 billion	Patent-protected, high-income dominance
2018	$600 million	Patent expiry, beginning generic uptake
2022	$2.0 billion (global generics sales)	Predominantly generics in LMICs; minimal branded sales

Forecasted Market Performance (2023-2030)

Year	Projected Revenue (USD)	CAGR	Key Assumptions
2023	$2.1 billion	4%	Growing demand in LMICs, stable pricing
2025	$2.5 billion	4%	Increased procurement via global initiatives
2030	$3.3 billion	4-5%	Steady growth in emerging markets

Key Revenue Components

Component	Share (%)	Notes
Generic Sales	85-90%	Primary income stream
Branded Sales	10-15%	Residual in certain markets (e.g., US, EU)
Licensing & Royalties	Variable	Minimal post-generics

---

5. Comparative Analysis

Aspect	Efavirenz	Dolutegravir (e.g., Tivicay)	Rilpivirine (e.g., Edurant)
Market Penetration	High in LMICs	Increasing globally	Complementary in ART mixes
Resistance Profile	Resistance concerns over time	Greater barrier	Resistance patterns similar
Pricing	Very low in generics	Higher per unit	Mid-range
Regulatory Status	Widely approved	Widely approved	Widely approved

---

6. Future Outlook and Opportunities

Opportunity Area	Description	Implication for Investment
Combination Therapies	Fixed-dose combinations with integrase inhibitors	Potential growth in high-income markets
Long-Acting Formulations	Investigational long-acting injectables	Disrupts oral therapy; future paradigm shift
New Indications	Off-label uses or resistance management	Unlikely but possible

Potential Risks

• Emergence of Resistance: Could limit market value.
• Regulatory Changes: Policies favor newer drug classes.
• Market Shift: Movement toward integrase inhibitors and long-acting injectables.

---

Conclusion: Investment Outlook

• Stable Long-term Revenue: Dominated by generic markets in LMICs, projected growth driven by expanding access.
• Market Saturation in Developed Countries: Declining sales as newer therapies replace efavirenz.
• Emerging Opportunities: Combination formulations, long-acting injectables, and strategic partnerships.
• Risk Profile: Moderate; primarily driven by competitive dynamics and evolving treatment guidelines.

---

Key Takeaways

• Efavirenz remains essential in global HIV treatment, especially in resource-limited settings.
• Generic proliferation post-patent expiry drastically reduced unit prices but scaled volume.
• The future financial trajectory will be shaped by emerging treatment modalities and access expansion.
• Companies should invest in derivative formulations and combination therapies to sustain growth.
• Monitoring resistance patterns, regulatory policies, and global health initiatives remains critical.

---

FAQs

1. What is the current patent status of efavirenz?
Most patents expired globally around 2018-2019, enabling widespread generic manufacturing, with some jurisdictions still referencing residual or supplementary patents.

2. How does efavirenz market share differ between developed and developing countries?
In developed markets (e.g., US, EU), efavirenz has been largely replaced by newer agents like dolutegravir. In contrast, in LMICs, efavirenz maintains a dominant share owing to affordability and established procurement channels.

3. What emerging therapies threaten efavirenz's market position?
Long-acting injectable integrase inhibitors (e.g., cabotegravir), and next-generation drugs with improved resistance profiles, are poised to replace efavirenz in many settings.

4. How do international health organizations influence efavirenz's market?
WHO prequalification and inclusion in the essential medicines list enforce broad access via global vaccination initiatives, securing sustained demand particularly in resource-limited settings.

5. What strategic moves should pharmaceutical companies consider concerning efavirenz?
Investing in fixed-dose combination formulations, expanding access programs, and exploring long-acting injectable forms can sustain revenue streams and competitive edges.

---

References

[1] WHO. "Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring." 2021.

[2] IMS Health. "Global HIV/AIDS Market Analysis 2022."

[3] US Patent and Trademark Office. "Efavirenz Patent Status," 2019.

[4] Gilead Sciences. "Market Reports on HIV Therapies," 2022.

[5] World Bank. "Access to HIV Treatment in LMICs," 2021.

---

This comprehensive assessment synthesizes current data to assist stakeholders in making informed investment decisions regarding efavirenz.